Author:
Brenes Jorge A,Cha Yong-Mei
Abstract
Diltiazem is a calcium channel blocker commonly used in the treatment of various cardiovascular disorders such as hypertension, angina and supraventricular tachycardias. Metabolism occurs mainly in the liver, but a small percentage of unchanged drug and metabolites are excreted in the urine. Toxicity from this medication usually presents in the form of dysrrhytmias and heart block. Hence, we present a case of complete atrioventricular AV block in a patient receiving sustained- release diltiazem on a chronic basis. Risk factors such as advanced age and impaired renal function are dis-cussed.
Publisher
Bentham Science Publishers Ltd.
Subject
Cardiology and Cardiovascular Medicine
Reference9 articles.
1. Willis BK, Liu JM, Wahl M.
Third-degree AV block from extended-release diltiazem ingestion in a nine-month old
J Emerg Med
2010;
38
(3
)
: 328-1.
2. Pozet N, Brazier JL, Aissa AH, et al.
Pharmacokinetics of diltiazem in renal failure
Eur J Clin Pharmacol
1983;
24
: 635-8.
3. Rahn KH, Van Bortel LM, Mooy JM.
The use of calcium channel blockers in patients with renal failure
J Hypertens journal
1987;
5
(54
)
: 567-9.
4. Andrivet P, Beasley V, Kiger JP, Vu Gnoc C.
Complete sinus arrest during diltiazem therapy: clinical correlates and efficacy of intravenous calcium
Eur Heart J
1994;
15
: 350-4.
5. Patel R, Lipper B, Schwartzbard A, Nelson C, O’Connor MA, Frishman W.
Toxic effects of diltiazem in a patient with chronic renal failure
J Clin Pharmacol
1994;
34
: 273-4.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献